CONTERA PHARMA A/S

CVR33062214

Core data

Name
CONTERA PHARMA A/S
Address
Venlighedsvej 4, 2970, Hørsholm
Founded
Jul 9, 2010
21 / 19
Locations (P-units)
1View locations
Website
https://conterapharma.com/
LinkedIn
contera-pharma
VAT registered
Branch
Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)

Keep track of CONTERA PHARMA A/S

Get an email when we detect changes to financial reports, ownership, management or property trades. Save yourself checking the company again.
Free account

Description

Contera Pharma is a Danish biotech company transforming RNA therapeutics with a proprietary discovery platform that uncovers new opportunities in diseases with significant unmet needs. It develops innovative treatments for neurological disorders.

Contera Pharma uses a precision medicine approach and a proprietary discovery platform to identify human disease-validated drug discovery targets and develop novel therapeutic and pipeline opportunities for neurological disorders. It also pursues partnerships and licensing opportunities.

Company's own description on virk.dk

Description of key activities of the companyLike previous years, the activities are development of new pharmaceuticals and other related activities.

Products & services

Proprietary RNA therapeutics discovery platform · Drug discovery target identification · CP-012 for Parkinson’s disease · CP-102 antisense oligonucleotide therapy for Canavan disease · Research collaborations · Partnering and licensing opportunities

Industries

Biotechnology · Pharmaceutical drug discovery · RNA therapeutics · Neurological disorders

Customer types

Patients with neurological disorders · Academic institutions and companies

Analysis by AI ✨

Contera Pharma reported a markedly improved result in 2025 compared with the previous year: gross profit was DKK 20.6 million, against DKK -54.1 million in 2024, and profit after tax was DKK -4.8 million, against DKK -69.2 million. The annual report describes the company's activities as developing new pharmaceuticals and related activities.

The workforce grew from 20 employees in July 2026 to 21 in August 2026. The company is based in Hørsholm; its current address, Venlighedsvej 4, has been in effect since 10 October 2022.

Bukwang Pharmaceutical Co., Ltd currently owns 90–99.99% of Contera Pharma. The South Korean company has been an owner since 24 November 2014, with historical changes in its ownership stake; its currently registered stake is 90–99.99%. Medici 2020-1 Private Equity Fund, a South Korean fund, held a historical stake of 25–33.32% from 22 July 2020 to 1 April 2024.

The share capital was increased by a nominal DKK 1,490,566 on 14 July 2026. The latest annual report also states that, after the financial year ended, the board decided to initiate a process aimed at a demerger; it was expected to be completed in 2026 and was subject to approval by the general meeting and relevant authorities.

AI-generated texts are based on registered information, which may be delayed or incomplete. Errors may occur.

Financials

Company financials
Reporting period
Gross profit
20,632,306
Operating profit
-5,983,680
Profit before tax
-6,062,659
Net income
-4,783,781
Total assets
97,550,947
Equity
79,471,802
Avg. employees
14
2017–2025

Unlock financial history

Datapublica Risk Score

Locked
Assesses the risk of financial distress using the company’s accounts, history, and connections.
Company score
0 · Low100 · High

What goes into the assessment

  • Financials

  • Accounts and history

  • Owners and management

  • Company and connections

Standard: Score and risk bandPro: Also a detailed explanation of the factors

Contact

From cvr.dk

Company
3118****Show full
**@conterapharma.comShow full

From conterapharma.com

Main
in**@conterapharma.comShow full

2 consecutive growth years

Børsen Gazelle is Dagbladet Børsen's award. Datapublica is not affiliated with Børsen. Calculated statuses are Datapublica's own analysis of public CVR financial-statement data.

People

Paul Ejnar Gremaud KristjansenRoles
Board
TitlesBESTYRELSESMEDLEM
Thomas Nikolaj SagerRoles
BoardManagement
TitlesBESTYRELSESMEDLEM • ADM. DIR.

Auditor

PKF Munkebo Eriksen Funch, Statsautoriseret Revisions aktie selskabAuditorThomas FunchRoleStatsautoriseret revisorFromApr 15, 2026

Foreign legal entity

Ownership90–99.99 %Voting rights90 %FromApr 1, 2024

Ultimate owners

🇰🇷Bukwang Pharmaceutical Co., Ltd
Ownership through
Direct
90–99.99 %

Official sources